WO2018164113A1 - マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 - Google Patents
マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 Download PDFInfo
- Publication number
- WO2018164113A1 WO2018164113A1 PCT/JP2018/008554 JP2018008554W WO2018164113A1 WO 2018164113 A1 WO2018164113 A1 WO 2018164113A1 JP 2018008554 W JP2018008554 W JP 2018008554W WO 2018164113 A1 WO2018164113 A1 WO 2018164113A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myopia
- mouse
- endoplasmic reticulum
- reticulum stress
- lens
- Prior art date
Links
- 230000004379 myopia Effects 0.000 title claims abstract description 143
- 208000001491 myopia Diseases 0.000 title claims abstract description 143
- 210000002472 endoplasmic reticulum Anatomy 0.000 title claims abstract description 59
- 230000006698 induction Effects 0.000 title claims abstract description 46
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 241001529936 Murinae Species 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000001012 protector Effects 0.000 claims abstract description 13
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims abstract description 13
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000001508 eye Anatomy 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 19
- 230000004329 axial myopia Effects 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003889 eye drop Substances 0.000 claims description 10
- 230000001629 suppression Effects 0.000 claims description 10
- 230000007246 mechanism Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000010172 mouse model Methods 0.000 claims description 8
- PRWSIEBRGXYXAJ-UHFFFAOYSA-N GSK2656157 Chemical compound CC1=CC=CC(CC(=O)N2C3=C(C(=C(C=4C5=C(N)N=CN=C5N(C)C=4)C=C3)F)CC2)=N1 PRWSIEBRGXYXAJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- SIXVRXARNAVBTC-UHFFFAOYSA-N gsk2606414 Chemical compound C12=C(N)N=CN=C2N(C)C=C1C(C=C1CC2)=CC=C1N2C(=O)CC1=CC=CC(C(F)(F)F)=C1 SIXVRXARNAVBTC-UHFFFAOYSA-N 0.000 claims description 5
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 5
- 229960000884 nelfinavir Drugs 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- HJGMCDHQPXTGAV-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-[[2-(4-chlorophenoxy)acetyl]amino]cyclohexyl]acetamide Chemical compound C1=CC(Cl)=CC=C1OCC(=O)NC1CCC(NC(=O)COC=2C=CC(Cl)=CC=2)CC1 HJGMCDHQPXTGAV-UHFFFAOYSA-N 0.000 claims description 4
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 claims description 4
- 229960004553 guanabenz Drugs 0.000 claims description 4
- LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 claims description 3
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 claims description 3
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 claims description 3
- SBYAVOHNDJTVPA-UHFFFAOYSA-N Isocarbamid Chemical compound CC(C)CNC(=O)N1CCNC1=O SBYAVOHNDJTVPA-UHFFFAOYSA-N 0.000 claims description 3
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 claims description 3
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 claims description 3
- 230000000384 rearing effect Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000004340 degenerative myopia Effects 0.000 claims description 2
- 208000001309 degenerative myopia Diseases 0.000 claims description 2
- 210000003786 sclera Anatomy 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000004402 high myopia Effects 0.000 abstract 1
- 230000000366 juvenile effect Effects 0.000 abstract 1
- 210000000695 crystalline len Anatomy 0.000 description 68
- 241000699666 Mus <mouse, genus> Species 0.000 description 42
- 230000004323 axial length Effects 0.000 description 31
- 230000008859 change Effects 0.000 description 18
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 16
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 102000007481 Activating Transcription Factor 6 Human genes 0.000 description 6
- 108010085405 Activating Transcription Factor 6 Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000004515 progressive myopia Effects 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- TVIVJHZHPKNDAQ-MHWRWJLKSA-N chembl3192687 Chemical compound OC1=CC=C2C=CC=CC2=C1\C=N\S(=O)(=O)C1=CC=CS1 TVIVJHZHPKNDAQ-MHWRWJLKSA-N 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 239000003885 eye ointment Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 4
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 alkali metal salts Chemical class 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002969 morbid Effects 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 3
- 241000234671 Ananas Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004353 induced myopia Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004331 refractive myopia Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009211 stress pathway Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IVQVBMWPWPTSNO-UHFFFAOYSA-N 2-hydroxy-6-[5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl]naphthalene-1-carbaldehyde Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=2C=C3C=CC(O)=C(C=O)C3=CC=2)S1 IVQVBMWPWPTSNO-UHFFFAOYSA-N 0.000 description 1
- IBOGLVJBKWHXOJ-UHFFFAOYSA-N 2-phenylbutanoic acid;sodium Chemical compound [Na].CCC(C(O)=O)C1=CC=CC=C1 IBOGLVJBKWHXOJ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- LLPWNQMSUYAGQI-QBQUQATFSA-N Ginsenoside R1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LLPWNQMSUYAGQI-QBQUQATFSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 101100433290 Homo sapiens ZNF471 gene Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100389697 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ERP1 gene Proteins 0.000 description 1
- XOKJUSAYZUAMGJ-UHFFFAOYSA-N Toyocamycin Natural products C1=C(C#N)C=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O XOKJUSAYZUAMGJ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101100066419 Xenopus laevis fbxo43 gene Proteins 0.000 description 1
- 102100029037 Zinc finger protein 471 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 229930193445 elatoside Natural products 0.000 description 1
- JTSXPAAHHFBNOT-UHFFFAOYSA-N elatoside C Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7OC8OCC(O)C(O)C8O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)OC9OC(CO)C(O)C(O)C9O JTSXPAAHHFBNOT-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- CVRPVRHBAOPDIG-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 1,3-dioxo-2-benzofuran-5-carboxylate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCOC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 CVRPVRHBAOPDIG-UHFFFAOYSA-N 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- XOKJUSAYZUAMGJ-WOUKDFQISA-N toyocamycin Chemical compound C1=C(C#N)C=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XOKJUSAYZUAMGJ-WOUKDFQISA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/06—Lenses; Lens systems ; Methods of designing lenses bifocal; multifocal ; progressive
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a method for producing a mouse myopia induction model for elucidating the mechanism of occurrence of myopia, and a drug that suppresses myopia.
- East Asians are said to have a higher percentage of myopia than Westerners, and at least about 1/3 of the population, that is, about 40 million people are said to be myopic. Nevertheless, no molecular mechanism for the onset and progression of myopia has been elucidated, and even if correction has been performed with glasses or contact lenses, there is no fundamental cure.
- Myopia is a condition where it is not clearly visible because it is focused in front of the retina.
- Myopia is roughly divided into two types: refractive myopia caused by the refractive index of the cornea and the crystalline lens being too strong, and axial myopia caused by the length of the eyeball in the longitudinal direction of the eyeball being too long.
- Refractive myopia is a condition in which the lens thickness that plays the role of the lens does not adjust well and the focus is in front of the retina.
- Axis myopia is a long eye axis, so even if the lens is adjusted to be thin enough A state where the focus is in front of the retina (see FIG. 1, axial myopia). Most patients with myopia have axial myopia.
- Non-patent Document 1 myopia research has been conducted by inducing myopia in animals such as chicks, pineapples, and guinea pigs.
- chicks are diurnal, have a relatively large eye, and are easy to handle. Therefore, chicks are widely used as model animals for myopia research, and 35 years have passed since myopia models using chicks were introduced. Even now, it has been used as the main myopia model.
- a variety of animals are used in myopia studies, including pineapple, marmoset, guinea pig, and rhesus monkey. However, none of these animals can be genetically manipulated easily and are not suitable for studying the genetic elements of myopia.
- the occurrence frequency of myopia has a racial difference as described above, it is considered that genetic factors are large in addition to environmental factors.
- the lack of a myopia-inducing model animal capable of studying genetic elements contributes to the establishment of a treatment method for suppressing myopia.
- the currently reported mouse model does not satisfy all of the symptoms known as symptoms of intense myopia in humans. That is, it does not satisfy the symptoms such as the degree of extension of the axial length, the refractive index and the sclera being thinner than normal, and is incomplete as a myopia model.
- An object of the present invention is to produce a mouse model having myopia that closely resembles the symptoms of intense myopia in humans.
- the conventional mouse model cannot be easily removed because the lens is sutured to the skin and further reinforced and fixed with an adhesive. For this reason, it has been difficult to observe changes with time as myopia progresses. It is an object of the present invention to analyze a process of myopia progression using a mouse myopia induction model, search for a therapeutic agent for myopia based on the obtained knowledge, and obtain a therapeutic agent that suppresses myopia.
- the present invention relates to the following myopia preventive / suppressor, a method for producing a mouse myopia induction model, a mouse myopia induction model produced by the production method, and a pharmaceutical screening method using the mouse myopia induction model.
- a myopia prevention / suppression agent comprising an endoplasmic reticulum stress inhibitor as an active ingredient.
- the endoplasmic reticulum stress inhibitor is phenylbutyric acid, tauroursodeoxycholic acid, salubrinal, guanabenz, GSK2606414, GSK2656157, ISRIB, azolamide, arctigenin or a pharmacologically acceptable salt thereof.
- the myopia preventive / suppressor according to (1).
- Agent. (4) The myopia preventing / suppressing agent according to any one of (1) to (3), wherein the myopia is axial myopia.
- a method for preparing a mouse myopia induction model comprising mounting a protector and a minus lens in front of the eyes of a young mouse and rearing the mouse with an angle and a width adjusted by an adjusting mechanism according to the growth of the mouse.
- a candidate substance is administered to a mouse model in which a protector and a minus lens are attached to the eyes of a young mouse, and the angle and width are adjusted by an adjustment mechanism according to the growth of the mouse to induce myopia.
- Myopia prevention / suppression drug screening method A mouse myopia induction model produced by mounting a protector and a minus lens in front of the eyes of a young mouse and rearing the mouse with the angle and width adjusted by an adjusting mechanism according to the growth of the mouse.
- a mouse myopia induction model with the same symptoms as those observed in human intense myopia was prepared. Mice can provide a good tool for studying the genetic factors of myopia because they have better genetic manipulation techniques than other animals. As a result of analysis of this model mouse, it was revealed that endoplasmic reticulum stress occurs in the sclera with myopia induction. Furthermore, since myopia was induced by applying endoplasmic reticulum stress, it was shown that myopia was induced by endoplasmic reticulum stress. In addition, experiments using a mouse myopia induction model revealed that endoplasmic reticulum stress inhibitors are effective in suppressing myopia. Therefore, it has become possible to provide a therapeutic agent in myopia where there has been no effective treatment until now.
- mouth myopia induction model The figure which shows the change of the refraction value of the mouse myopia guidance model, the axial length, and the sclera.
- An electron microscope image showing changes in the sclera of a mouse myopia induction model.
- 4A shows the refraction value
- FIG. 4B shows the axial length
- FIG. 4C shows the change in the axial length after one week of lens wearing and after 3 weeks.
- the figure which shows the effect with respect to myopia induction of the taurursodeoxycholic acid which is an endoplasmic reticulum stress inhibitor The figure which shows the effect with respect to myopia induction of sodium phenylbutyrate by eye drops. The figure which shows the result of having analyzed myopia induction by the endoplasmic reticulum stress inducer. The figure which shows the effect of the compound which inhibits the signal pathway of a different endoplasmic reticulum stress sensor. 8A shows the refraction value, and FIG. 8B shows the analysis result of the axial length.
- the present inventors have revealed for the first time that endoplasmic reticulum stress occurs in the sclera when myopia is induced.
- endoplasmic reticulum stress affects corneal endothelial cells and causes numerous diseases (Patent Document 1).
- Patent Document 1 it has not been reported so far that myopia and endoplasmic reticulum stress are correlated or that myopia is induced by endoplasmic reticulum stress.
- the present inventors have discovered for the first time that the progression of myopia is suppressed by an endoplasmic reticulum stress inhibitor.
- Non-Patent Documents 1 and 2 myopia induction models have been produced in various animals so far, and myopia induction models for mice have also been reported (Non-Patent Documents 1 and 2).
- no model has been reported so far in which all the same symptoms as human myopia, i.e., changes in refractive value, axial length, and sclera, are observed.
- a mouse model exhibiting symptoms similar to those of humans could be produced for the first time by the inventor's method. This makes it possible to study genetic factors for myopia that have not been clarified so far, and it becomes possible to screen for drugs that provide fundamental treatment for myopia.
- the present inventors have found that an endoplasmic reticulum stress inhibitor suppresses myopia induction in a mouse model.
- the candidate compound When screening for a myopia prevention / suppressor, the candidate compound may be administered at any timing. That is, administration of the candidate compound may be started immediately after the start of myopia induction, or administration of the candidate compound may be started after some symptoms of axial myopia are observed after the start of myopia induction. Further, the administration period and timing can be appropriately determined depending on the candidate compound.
- the administration of the myopia suppressant is carried out by intraperitoneal administration and instillation here, but any administration form may be used. Specifically, administration by injection, application by eye drops, eye ointment, or oral administration may be used. Therefore, the dosage form may be an eye drop, an eye ointment, or a dosage form suitable for internal use such as tablets and capsules in addition to the injection. In particular, eye drops and eye ointments are preferable because they can be directly applied to the eye.
- sodium phenylbutyric acid (4-phenylbutyric acid, 4-PBA) and taursodeoxycholic acid (TUDCA) are used as endoplasmic reticulum stress inhibitors. It may be other salts acceptable to the above. Pharmacologically acceptable salts include alkali metal salts, alkaline earth metal salts, amines or basic amino acid addition salts.
- any drug that can suppress endoplasmic reticulum stress may be used.
- Chemical chaperones that contribute to the formation and stabilization of higher-order protein structures such as sodium phenylbutyrate, tauroursodeoxycholic acid, and trehalose are said to reduce endoplasmic reticulum stress.
- the endoplasmic reticulum stress signal can also be suppressed by inhibiting the signal downstream of the endoplasmic reticulum stress sensor (Non-patent Documents 3-5).
- any compound that has an action of reducing endoplasmic reticulum stress or suppressing a signal generated from the endoplasmic reticulum stress sensor may act as a myopia prevention / suppression agent.
- Endoplasmic reticulum stress is detected by three stress sensors, and signals are transmitted downstream so as not to accumulate excessively folded proteins.
- ERP1 non-patent literature
- PERK PSR-like endoplasmic reticulum kinase
- IRE1 Inositol requiring 1
- ATF6 Activating transcription factor 6
- Such drugs include Salubrinal, Guanabenz, GSK2606414, GSK2656157, ISRIB, STF-083010, MKC-3946, Toyocamycin (Nelfinavib (Nelfinavib), Nelfinavib (Nelfinavib) -Hydroxy-4-methyl-2-oxo-2H-1-benzopyran-8-carbodealdehyde) (Non-patent Document 5).
- the drugs of the PERK pathway and the ATF6 pathway are effective.
- Patent Document 2 discloses PERK inhibitors including GSK2606414 and GSK2656157. Needless to say, the inhibitor described in Patent Document 2 can also be used.
- Non-patent Documents 7 and 8 Azolamide and Arctigenin are thought to inhibit endoplasmic reticulum stress upstream. Therefore, these drugs are also considered to act as myopia suppressants.
- Astragalaside IV Astragalaside IV
- baicalein Baicalein
- berberine Berberine
- crocin Rosin
- Elatoside Cb ginsenoside Rb1
- Examples of compounds that suppress endoplasmic reticulum stress include Honokiol Ikariin, Mangiferin, Notoginsenoside R1, and Pterostilbene (Non-patent Document 9).
- FIG. 1 schematically shows a mechanism that induces axial myopia by wearing a minus lens.
- Normal vision refers to a state where the image is clearly visible because parallel rays entering the eye form an image on the retina.
- axial myopia refers to a state in which the collimated rays entering the eyes form an image in front of the retina because the length of the eye axis is long, so that it cannot be clearly seen.
- the eye axis When a minus lens is worn on a young mouse, the eye axis extends to a position where an image is formed when the minus lens is worn, that is, a state where it can be clearly seen when the minus lens is worn. As a result, the eye axis extends, and an eye state similar to axial myopia can be created.
- a mouse myopia guidance model is prepared as follows. Since young mice are more likely to induce myopia, it is desirable to attach a minus lens as soon as possible after weaning. Here, 3 weeks old C57BL6J is used. The mouse is anesthetized with three types of mixed anesthesia of Domitor (Nippon Zenyaku Kogyo Co., Ltd.), Betolfal (Meiji Seika Pharma Co., Ltd.) and Midazolam (Sand Corp.), and the skull is exposed with scissors. The column 1 is erected on the skull and fixed with dental cement (Super-Bond, Sun Medical Co., Ltd.). The support column is provided with a thread so that an adjusting device described later can be fixed with a nut.
- -30 diopter (D) minus lens (Rainbow Contact, Rainbow Optical Laboratory Co., Ltd.) 2 is attached to one side and 0D lens as a control, or only frame 3 is attached to the other side.
- a protector 4 having a shape protruding sideways is bonded to the frame portion below the lens so that the mouse is not damaged by the front legs or the like.
- the protector 4 prevents the mouse from touching the lens and does not damage the lens.
- the protector 4 is bonded to and integrated with the frame portion.
- the protector 4 is not required to be integrated with the lens as long as the lens is not damaged by the action of the mouse. For example, it may have a shape such as an Elizabeth collar worn by an injured animal.
- the adjusting device 5 for adjusting the width and angle of the mounted lens is adhered to the frame portion above the lens in accordance with the growth of the mouse.
- the adjusting device 5 is bent into a “ ⁇ ” shape, and one has a lens attached thereto, and the other has a long hole 6 so that it can be attached to the column 1 standing on the head.
- Width and angle can be adjusted according to the growth of the mouse, and the lens can be adjusted to the position of the eye of the mouse by the adjustment mechanism consisting of three points, the support column 1, the nut 7, and the adjusting device 5.
- the lens can be removed, it is possible to measure temporal changes in the axial length and the refractive value. As described above, changes in myopia progression over time could not be observed with the conventional model, but the lens can be easily removed with this myopia guidance model, so the myopia progression can be analyzed in more detail. Can now.
- Refractive values are refractometers (Infrared photorefractor for mice, produced by Prof. Schaeffel, Tubingen University), SD-OCT (Spectral-domain OCT, Spectral domain optical coherence tomography, Envisu R4310, biooptimized film thickness of Biot.
- the obtained paraffin sections were measured with an imaging software cellSens after acquiring an optical image with an optical microscope (BX53, Olympus Corporation). The results were analyzed by ANOVA and Turkey HSD.
- the refractive value, the axial length, and the thickness of the sclera were all significantly different from the control in the eyes in which myopia was induced by the -30D lens (* in the figure).
- Regarding the thickness of the sclera it was observed that the thickness of the sclera was thinner in the myopic eye than in the normal eye, regardless of the distance from the optic disc.
- the myopia guidance model produced in this example has all the characteristics of human axial myopia, indicating that it can be an excellent model. This is because the myopia guidance model allows the position of the lens to be fine-tuned as it grows, and since a protector for protecting the lens is provided, the lens is not damaged, and axial myopia is prevented. This is thought to be because it can be induced more significantly.
- Example 2 Screening of therapeutic agents using mouse myopia induction model
- analysis was performed using a transmission electron microscope (TEM).
- TEM transmission electron microscope
- the eyeball in which a negative lens was worn for 3 weeks to induce axial myopia, and the eyeball that had only been worn with a frame as a control were removed from the mouse, and 2.5% glutaraldehyde / saline solution for 1 hour at 4 ° C. Fixed.
- the cornea was removed, followed by post-fixation overnight with 2.5% glutaraldehyde / saline, embedded in Epok812 (Oken Shoji Co., Ltd.), sliced, and TEM (JEM-1400plus, JEOL Ltd.) was observed.
- the scale is 1.0 ⁇ m, 500 nm, and 500 nm from the left.
- the mouse sclera is mostly composed of collagen fibers and fibroblasts. Control fibroblasts are rich in mitochondria and rough endoplasmic reticulum (indicated by the upper arrow). On the other hand, a large number of expanded vacuolar ERs were observed in the sclera of the mouse in which myopia was induced by a minus lens (indicated by the lower arrow), suggesting that endoplasmic reticulum stress occurred.
- FIG. 4 (A) shows the amount of change in the refractive value.
- a group administered with PBS as a control when a -30D lens was worn, a significant change in refractive value was observed, but in a group administered with sodium phenylbutyrate (4-PBA), a -30D lens was used. There was no change in the refractive value between the eye wearing the eye and the eye wearing only the frame, and it was shown that sodium phenylbutyrate has a myopia suppression effect.
- the change of the axial length is shown in FIG.
- the sodium phenylbutyrate administration group no difference in elongation was observed when comparing the axial length of the eye wearing the minus lens and the eye wearing only the control frame.
- the axial length of the eye wearing the minus lens was significantly extended compared to the minus lens wearing group of the sodium phenylbutyrate administration group.
- FIG. 4C shows the length of the axial length after 1 week and 3 weeks after lens wearing.
- the eye wearing the minus lens of the PBS administration group has a significant extension to the control eye without lens and the lens wearing eye and non-wearing eye of the sodium phenylbutyrate administration group one week after the lens wearing.
- the axial length at 3 weeks after the start of lens wearing is elongated in all groups compared to the axial length at 1 week after the start of lens wearing. Even in the sodium phenylbutyrate administration group, the same degree of elongation as the axial length of the eyes wearing only the frame of the PBS administration group is observed. Indicates no effect.
- tauroursodeoxycholic acid was administered in spite of a significant change in refractive value between the eye wearing the ⁇ 30D lens and the eye wearing only the frame. In the group, there was no difference between the two, and tauroursodeoxycholic acid was found to have a myopia-inhibiting effect. In addition, with respect to changes in the axial length, a significant difference was observed between the group administered with tauroursodeoxycholic acid and the PBS-administered group in the eyes subjected to myopia induction. In contrast, it was revealed that tauroursodeoxycholic acid has an effect.
- Efficacy of endoplasmic reticulum stress-inhibiting agent As an agent that suppresses myopia, a dosage form that can be administered directly to the eye, such as eye drops or eye ointments, is highly effective, and patients themselves Is desirable because it can be administered. Therefore, a mouse myopia induction model was prepared in the same manner as in Example 1, and the effect of instillation of sodium phenylbutyrate was analyzed.
- a control group (n 4) received PBS instillation.
- mice 50 ⁇ g / ml tunicamycin (Tm) (SIGMA Aldrich) or 10 ⁇ M thapsigargin (TG) (Wako Pure Chemical Industries, Ltd.) is applied to the right eye, and PBS (Veh) is applied once to the left eye. Administered. The refractive value and the axial length were measured before and 1 week after administration of tunicamycin and thapsigargin, and the amount of change was calculated (FIG. 7).
- tunicamycin which is known as an endoplasmic reticulum stress inducer
- endoplasmic reticulum stress inducer showed significant differences in both refractive value and axial length of the PBS-administered eye, and induced myopia. That is, it was shown that endoplasmic reticulum stress directly induced myopia.
- Example 4 Effect of endoplasmic reticulum stress pathway inhibitor on myopia induction As described above, it is known that there are three pathways downstream of endoplasmic reticulum stress: the IRE1 pathway, the PERK pathway, and the ATF6 pathway. Using inhibitors of three pathways of the endoplasmic reticulum stress pathway, it was analyzed whether there was an effect of suppressing myopia induction.
- STF-083010 STF was used as an inhibitor of the IRE1 pathway
- GSK265615 GSK265615
- NFV Nelfinavir
- Example 1 3-week-old male C57BL6J mice were worn with a -30D lens on the right eye and only a frame on the left eye.
- a solution dissolved in PBS so that n 3) was administered by eye drop every day.
- 0.1% DMSO (SIGMA Aldrich Co.) was dissolved in PBS and administered by eye drops.
- the refractive value and the axial length were measured before lens wearing and one week after wearing, and the amount of change was calculated (FIG. 8).
- the difference (change amount) between the refractive values before and after the lens wearing (FIG. 8A) and the axial length (FIG. 8B) is changed to the left, and the difference of the change amount in each individual is compared. Therefore, the difference between the change amount of the lens wearing eye and the change amount of the control eye is obtained and represented as a graph on the right side.
- STF-083010 like DMSO, produced significant changes in the refractive value and the axial length of the control eye that did not wear the lens, and did not suppress myopia induction.
- DMSO dimethyl methacrylate
- a change in refractive value and an increase in the axial length were observed even in the control eye not wearing the lens.
- the difference in the amount of change from the eye wearing the lens and inducing myopia is significantly reduced (the graphs on the right in FIGS. 8A and 8B), there is an effect of suppressing myopia induction. it is conceivable that.
- endoplasmic reticulum stress inhibitors suppress the progression of myopia in contrast to myopia where there was no effective therapeutic agent. Therefore, the endoplasmic reticulum stress inhibitor can act as a therapeutic agent for myopia.
- a myopia induction model exhibiting symptoms similar to those of human myopia could be created using mice that can be easily genetically analyzed. In the future, by using a mouse myopia induction model, it will be possible to elucidate the molecular mechanism of the onset of myopia and develop molecularly targeted drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Optics & Photonics (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
(1)小胞体ストレス抑制剤を有効成分として含有することを特徴とする近視予防・抑制剤。
(2)前記小胞体ストレス抑制剤がフェニル酪酸、タウロウルソデオキシコール酸、サルブリナル、グアナベンツ、GSK2606414、GSK2656157、ISRIB、アゾラミド、アークティゲニン又はそれらの薬理学的に許容される塩であることを特徴とする(1)記載の近視予防・抑制剤。
(3)前記小胞体ストレス抑制剤がフェニル酪酸、タウロウルソデオキシコール酸、又はそれらの薬理学的に許容される塩であることを特徴とする(1)又は(2)記載の近視予防・抑制剤。
(4)前記近視が軸性近視であることを特徴とする(1)~(3)いずれか1つ記載の近視予防・抑制剤。
(5)前記近視が病的近視であることを特徴とする(1)~(4)いずれか1つ記載の近視予防・抑制剤。
(6)剤形が点眼剤であることを特徴とする(1)~(5)いずれか1つ記載の近視予防・抑制剤。
(7)プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、マウスの成長に応じて調節機構により角度及び幅を調節して飼育することを特徴とするマウス近視誘導モデル作製方法。
(8)プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、マウスの成長に応じて調節機構により角度及び幅を調節し近視誘導を行うマウスモデルに、候補物質を投与することを特徴とする近視予防・抑制医薬スクリーニング方法。
(9)プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、マウスの成長に応じて調節機構により角度及び幅を調節して飼育することにより作製されたマウス近視誘導モデル。
まず、本発明のマウスモデルの作製方法について説明を行う。マイナスレンズを装用させて軸性近視が誘導される機構を図1に模式的に示している。正眼視は目に入ってくる平行光線が網膜上で像を結ぶことから、像がはっきりと見える状態をいう。一方、軸性近視は、眼軸長が長くなっているために目に入ってくる平行光線が網膜の手前で像を結ぶため、はっきりと見えない状態をいう。ヒトを含め、動物の眼は成長とともに大きくなる。幼若なマウスにマイナスレンズを装用させると、マイナスレンズを装用しているときに像を結ぶ位置、すなわちマイナスレンズ装用時にはっきりと見える状態まで眼軸が伸長する。その結果、眼軸が伸長し、軸性近視と同様の眼の状態を作り出すことができる。
近視誘導モデルの病態を詳細に調べるために、透過型電子顕微鏡(TEM)を用いて解析を行った。3週間マイナスレンズを装用させ軸性近視を誘導した眼球、及びコントロールとしてフレームのみを装用させていた眼球をマウスから摘出し、2.5%グルタールアルデヒド/生理食塩水で1時間、4℃で固定した。角膜を除去し、2.5%グルタールアルデヒド/生理食塩水で一晩、後固定を行い、Epok812(応研商事株式会社)で包埋し薄切しTEM(JEM-1400plus、日本電子株式会社)により観察した。図3の上段にコントロール、下段に-30Dレンズを装用させて近視誘導を行ったマウスから得た試料の強膜を示す。スケールは左から1.0μm、500nm、500nmである。
電子顕微鏡の観察結果から、近視誘導に伴って小胞体ストレスが生じていることが示唆された。そこで、小胞体ストレス抑制剤を投与し、近視誘導が抑制されるか解析を行った。小胞体ストレス抑制剤として、フェニル酪酸ナトリウム(Cayman株式会社)200mg/kg/dayの用量で、レンズ装用後2日目から21日目まで毎日腹腔内投与を行い、21日目に屈折値、眼軸長を測定した。なお、コントロール群には、PBSのみを投与した。
次に、同じく小胞体ストレス抑制剤として知られているタウロウルソデオキシコール酸の効果の解析を行った。実施例1と同様に、3週齢雄性C57BL6Jマウスを用いて解析を行った。マウスは右眼に-30Dのレンズを左眼にはフレームのみを装用した。レンズ装用当日から100mg/kg タウロウルソデオキシコール酸(SIGMA-Aldrich株式会社)を腹腔内投与により1日1回投与し(n=4)、対照群(n=4)にはPBSを等量腹腔内投与した。レンズ装用前、装用1週間後に眼軸長・屈折値を測定し、その変化量を算出した。図5左には屈折値を、右には眼軸長の変化を示す。
近視を抑制する薬剤として、点眼剤、あるいは眼軟膏のように直接目に投与することのできる剤形は、高い効果が望める点、また、患者自らが投与できることから望ましい。そこで、実施例1と同様にしてマウス近視誘導モデルを作製し、フェニル酪酸ナトリウムの点眼による効果を解析した。
上記で示したように、小胞体ストレスの抑制剤が近視誘導に対して抑制効果があることから、小胞体ストレスが近視誘導に直接的に関与しているものと考えられる。そこで、小胞体ストレスを誘導する薬剤を投与することによって、近視を誘導することができるか解析を行った。対象は3週齢雄性C57BL6Jマウス(n=12)とした。マウスには右眼に50μg/mlのツニカイマイシン(Tm)(SIGMA Aldrich株式会社)又は10μMのタプシガルギン(TG)(和光純薬工業株式会社)、左眼にはPBS(Veh)を1回点眼投与した。ツニカイマイシン、タプシガルギン投与前および1週間後に屈折値、及び眼軸長を測定し、その変化量を算出した(図7)。
上述のように、小胞体ストレスの下流には、IRE1経路、PERK経路、ATF6経路の3つの経路があることが知られている。小胞体ストレス経路の3つの経路の阻害剤を用いて、近視誘導抑制効果があるか解析を行った。
Claims (9)
- 小胞体ストレス抑制剤を有効成分として含有することを特徴とする近視予防・抑制剤。
- 前記小胞体ストレス抑制剤がフェニル酪酸、タウロウルソデオキシコール酸、サルブリナル、グアナベンツ、GSK2606414、GSK2656157、ISRIB、ネルフィナビル、アゾラミド、アークティゲニン又はそれらの薬理学的に許容される塩であることを特徴とする請求項1記載の近視予防・抑制剤。
- 前記小胞体ストレス抑制剤がフェニル酪酸、タウロウルソデオキシコール酸、又はそれらの薬理学的に許容される塩であることを特徴とする請求項1又は2記載の近視予防・抑制剤。
- 前記近視が軸性近視であることを特徴とする請求項1~3いずれか1項記載の近視予防・抑制剤。
- 前記近視が病的近視であることを特徴とする請求項1~4いずれか1項記載の近視予防・抑制剤。
- 剤形が点眼剤であることを特徴とする請求項1~5いずれか1項記載の近視予防・抑制剤。
- プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、
マウスの成長に応じて調節機構により角度及び幅を調節して飼育することを特徴とするマウス近視誘導モデル作製方法。 - プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、
マウスの成長に応じて調節機構により角度及び幅を調節し近視誘導を行うマウスモデルに、
候補物質を投与することを特徴とする近視予防・抑制医薬スクリーニング方法。 - プロテクター及びマイナスレンズを幼若マウスの眼前に装着し、
マウスの成長に応じて調節機構により角度及び幅を調節して飼育することにより作製されたマウス近視誘導モデル。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019504597A JP6637217B2 (ja) | 2017-03-06 | 2018-03-06 | 近視予防又は抑制剤、マウス近視誘導モデルの作製方法、及び、近視予防又は抑制医薬スクリーニング方法 |
EP18764652.6A EP3593817A4 (en) | 2017-03-06 | 2018-03-06 | MODEL FOR THE INDUCTION OF MURINE MYOPIA AND ENDOPLASMATIC RETICULUM STRESS INHIBITOR FOR THE PREVENTION OR SUPPRESSION OF MYOPIA |
KR1020197029237A KR102680012B1 (ko) | 2017-03-06 | 2018-03-06 | 근시 예방 또는 억제제, 마우스 근시 유도 모델의 제작 방법, 및 근시 예방 또는 억제 의약 스크리닝 방법 |
CN202211310272.2A CN115645536A (zh) | 2017-03-06 | 2018-03-06 | 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 |
CN201880016406.5A CN110392579B (zh) | 2017-03-06 | 2018-03-06 | 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 |
CN202211310191.2A CN115645535B (zh) | 2017-03-06 | 2018-03-06 | 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 |
US16/561,776 US20200150457A1 (en) | 2017-03-06 | 2019-09-05 | Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia |
US18/600,985 US20240210736A1 (en) | 2017-03-06 | 2024-03-11 | Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017041349 | 2017-03-06 | ||
JP2017-041349 | 2017-03-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/561,776 Continuation-In-Part US20200150457A1 (en) | 2017-03-06 | 2019-09-05 | Mouse myopia-induced model and endoplasmic reticulum stress suppressant for preventing and suppressing myopia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018164113A1 true WO2018164113A1 (ja) | 2018-09-13 |
Family
ID=63448602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/008554 WO2018164113A1 (ja) | 2017-03-06 | 2018-03-06 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20200150457A1 (ja) |
EP (1) | EP3593817A4 (ja) |
JP (5) | JP6637217B2 (ja) |
KR (1) | KR102680012B1 (ja) |
CN (3) | CN115645536A (ja) |
WO (1) | WO2018164113A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020129964A1 (ja) * | 2018-12-18 | 2020-06-25 | 参天製薬株式会社 | ウルソデオキシコール酸を含有する老視の治療または予防剤 |
WO2020129965A1 (ja) * | 2018-12-18 | 2020-06-25 | 参天製薬株式会社 | 4-フェニル酪酸を含有する老視の治療または予防剤 |
WO2022123837A1 (ja) | 2020-12-11 | 2022-06-16 | 株式会社坪田ラボ | 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法 |
WO2022196609A1 (ja) * | 2021-03-16 | 2022-09-22 | 学校法人慶應義塾 | 網膜変性抑制用組成物 |
EP3934754A4 (en) * | 2019-03-08 | 2022-11-23 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY FAILURE |
WO2023145578A1 (ja) * | 2022-01-25 | 2023-08-03 | 株式会社坪田ラボ | 薬剤点眼による近視誘導モデル |
KR20230135054A (ko) | 2020-12-11 | 2023-09-22 | 가부시키가이샤 쓰보타 라보 | 소아의 근시 진행 억제용 점안제 및 소아의 근시 진행억제제의 스크리닝 방법 |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
WO2023210657A1 (ja) * | 2022-04-26 | 2023-11-02 | 株式会社坪田ラボ | 近視を予防または治療するための方法および組成物 |
WO2024048697A1 (ja) * | 2022-08-31 | 2024-03-07 | 国立大学法人京都大学 | 化合物、小胞体ストレス抑制剤、医薬品、眼科用剤、点眼薬、組成物、化合物の製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3182437A1 (en) * | 2020-06-11 | 2021-12-16 | Andrei V. Tkatchenko | Methods and compositions for preventing and treating myopia with berberine, a berberidaceaen alkaloid, and derivatives thereof |
CN112970666B (zh) * | 2021-02-04 | 2023-02-03 | 复旦大学附属眼耳鼻喉科医院 | 一种简便式动物近视诱导装置及制作方法 |
CN116267712A (zh) * | 2023-02-23 | 2023-06-23 | 温州医科大学 | 一种近视眼动物模型的构建方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513465A (ja) * | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | 肥満及び糖尿病の治療におけるerストレス低減 |
WO2010010702A1 (ja) * | 2008-07-24 | 2010-01-28 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
JP2013534902A (ja) | 2010-03-25 | 2013-09-09 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物 |
WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
WO2016171282A1 (ja) * | 2015-04-24 | 2016-10-27 | 学校法人慶應義塾 | 近視予防剤及び近視進行抑制剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU775516B2 (en) | 2000-01-18 | 2004-08-05 | Trustees Of The University Of Pennsylvania, The | Ocular growth and nicotinic antagonists |
CN1191074C (zh) * | 2002-09-18 | 2005-03-02 | 王力 | 熊胆粉滴眼液及其制备方法 |
MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
US20060073213A1 (en) * | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
BR112012024380A2 (pt) * | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
US8962686B2 (en) * | 2010-04-28 | 2015-02-24 | The Chinese University Of Hong Kong | Method and medication for prevention and treatment of ocular hypertension and glaucoma |
EP2663653B1 (en) * | 2011-01-14 | 2018-04-11 | University of Washington through its Center for Commercialization | Methods for diagnosing and prescribing a treatment protocol for eye-length related disorders |
WO2013025840A1 (en) * | 2011-08-15 | 2013-02-21 | Massachusetts Eye And Ear Infirmary | Methods for preserving photoreceptor cell viability following retinal detachment |
WO2015056180A1 (en) * | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
CN112599133A (zh) | 2020-12-15 | 2021-04-02 | 北京百度网讯科技有限公司 | 基于车辆的语音处理方法、语音处理器、车载处理器 |
-
2018
- 2018-03-06 WO PCT/JP2018/008554 patent/WO2018164113A1/ja unknown
- 2018-03-06 CN CN202211310272.2A patent/CN115645536A/zh active Pending
- 2018-03-06 EP EP18764652.6A patent/EP3593817A4/en active Pending
- 2018-03-06 CN CN202211310191.2A patent/CN115645535B/zh active Active
- 2018-03-06 KR KR1020197029237A patent/KR102680012B1/ko active IP Right Grant
- 2018-03-06 JP JP2019504597A patent/JP6637217B2/ja active Active
- 2018-03-06 CN CN201880016406.5A patent/CN110392579B/zh active Active
-
2019
- 2019-09-05 US US16/561,776 patent/US20200150457A1/en active Pending
- 2019-11-07 JP JP2019202287A patent/JP6856275B2/ja active Active
-
2021
- 2021-03-11 JP JP2021038816A patent/JP7236753B2/ja active Active
-
2022
- 2022-12-09 JP JP2022197027A patent/JP7424676B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002286A patent/JP2024026709A/ja active Pending
- 2024-03-11 US US18/600,985 patent/US20240210736A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513465A (ja) * | 2004-09-15 | 2008-05-01 | ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ | 肥満及び糖尿病の治療におけるerストレス低減 |
WO2010010702A1 (ja) * | 2008-07-24 | 2010-01-28 | 国立大学法人大阪大学 | 軸性近視の予防または治療剤 |
JP2013534902A (ja) | 2010-03-25 | 2013-09-09 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物 |
WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
WO2016171282A1 (ja) * | 2015-04-24 | 2016-10-27 | 学校法人慶應義塾 | 近視予防剤及び近視進行抑制剤 |
Non-Patent Citations (14)
Title |
---|
CHEN Y. ET AL., SCIENTIFIC REPORTS, vol. 6, 2016, pages 27486 |
FU, S. ET AL.: "Phenotypic assays identify azoramide as a small-molecule modulator of the unfolded protein response with antidiabetic activity", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 292, 2015, pages 292ra98, XP055557634, ISSN: 1946-6242 * |
GU Y. ET AL., ACTA PHARMACOL. SINICA, vol. 33, 2012, pages 941 - 952 |
GU, Y. ET AL.: "Arctigenin alleviates ER stress via activating AMPK", ACTA PHARMACOLOGICA SINICA, vol. 33, no. 7, 2012, pages 941 - 952, XP055557639, ISSN: 1672-4083 * |
GUILLEN C., ANN. TRANSL. MED., 2016, pages S45 |
HATZ C. ET AL., NATURE REV. DRUG DISCOV., vol. 12, 2013, pages 703 - 719 |
HETZ C., NATURE REV. MOL. CELL BIOL., vol. 13, 2012, pages 89 - 102 |
HETZ, C.: "Targeting the unfolded protein response in disease", NATURE REVIEWS DRUG DISCOVERY, vol. 12, no. 9, 2013, pages 703 - 719, XP055557628, ISSN: 1474-1776 * |
KOLB P. S. ET AL., INT. J. BIOCHEM. CELL BIOL., vol. 61, 2015, pages 45 - 52 |
LIU H. ET AL., EVIDENCE-BASED COMPLE. ALTER. MED., vol. 2016, 2016 |
SCHAEFFEL F.FELDKAEMPER M., CLIN. EXP. OPTOM., vol. 98, 2015, pages 507 - 517 |
TKATCHENKO T. V. ET AL., INVEST. OPHTHALMOL. VIS. SCI., vol. 51, 2010, pages 1297 - 1303 |
TKATCHENKO, T. V. ET AL.: "Mouse experimental myopia has features of primate myopia", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 51, no. 3, 2010, pages 1297 - 1303, XP055561777 * |
ZHOU, S. ET AL.: "ER stress mediate crystalline alpha A alteration in high myopia related cataract", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 55, no. 13, 2014, pages 4054, XP009516554, ISSN: 0146-0404 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020129965A1 (ja) * | 2018-12-18 | 2020-06-25 | 参天製薬株式会社 | 4-フェニル酪酸を含有する老視の治療または予防剤 |
JP6771698B1 (ja) * | 2018-12-18 | 2020-10-21 | 参天製薬株式会社 | ウルソデオキシコール酸を含有する老視の治療または予防剤 |
CN113164499A (zh) * | 2018-12-18 | 2021-07-23 | 参天制药株式会社 | 含有熊去氧胆酸的老视的治疗或预防剂 |
CN113164421A (zh) * | 2018-12-18 | 2021-07-23 | 参天制药株式会社 | 含有4-苯基丁酸的老视的治疗或预防剂 |
JP7474706B2 (ja) | 2018-12-18 | 2024-04-25 | 参天製薬株式会社 | 4-フェニル酪酸を含有する老視の治療または予防剤 |
US11419880B2 (en) | 2018-12-18 | 2022-08-23 | Santen Pharmaceutical Co., Ltd. | Ursodeoxycholic acid-containing agent for treating or preventing presbyopia |
EP3900714A4 (en) * | 2018-12-18 | 2022-09-21 | Santen Pharmaceutical Co., Ltd. | AGENT CONTAINING 4-PHENYLBUTYRATE, FOR THE PREVENTION OR TREATMENT OF PRESBYOPIA |
WO2020129964A1 (ja) * | 2018-12-18 | 2020-06-25 | 参天製薬株式会社 | ウルソデオキシコール酸を含有する老視の治療または予防剤 |
EP3934754A4 (en) * | 2019-03-08 | 2022-11-23 | The Regents Of The University Of California | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY FAILURE |
KR20230135054A (ko) | 2020-12-11 | 2023-09-22 | 가부시키가이샤 쓰보타 라보 | 소아의 근시 진행 억제용 점안제 및 소아의 근시 진행억제제의 스크리닝 방법 |
KR20230135055A (ko) | 2020-12-11 | 2023-09-22 | 가부시키가이샤 쓰보타 라보 | 강막 비박화 치료용 점안제 및 강막 비박화 치료제의스크리닝 방법 |
WO2022123837A1 (ja) | 2020-12-11 | 2022-06-16 | 株式会社坪田ラボ | 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法 |
WO2022196609A1 (ja) * | 2021-03-16 | 2022-09-22 | 学校法人慶應義塾 | 網膜変性抑制用組成物 |
WO2023145578A1 (ja) * | 2022-01-25 | 2023-08-03 | 株式会社坪田ラボ | 薬剤点眼による近視誘導モデル |
WO2023182480A1 (ja) * | 2022-03-25 | 2023-09-28 | 株式会社坪田ラボ | 水性組成物 |
WO2023210657A1 (ja) * | 2022-04-26 | 2023-11-02 | 株式会社坪田ラボ | 近視を予防または治療するための方法および組成物 |
WO2024048697A1 (ja) * | 2022-08-31 | 2024-03-07 | 国立大学法人京都大学 | 化合物、小胞体ストレス抑制剤、医薬品、眼科用剤、点眼薬、組成物、化合物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20200150457A1 (en) | 2020-05-14 |
JP2021091731A (ja) | 2021-06-17 |
US20240210736A1 (en) | 2024-06-27 |
JP2020023574A (ja) | 2020-02-13 |
JP6856275B2 (ja) | 2021-04-07 |
JP2024026709A (ja) | 2024-02-28 |
JPWO2018164113A1 (ja) | 2019-06-27 |
JP7236753B2 (ja) | 2023-03-10 |
JP7424676B2 (ja) | 2024-01-30 |
CN110392579A (zh) | 2019-10-29 |
JP6637217B2 (ja) | 2020-01-29 |
KR102680012B1 (ko) | 2024-06-28 |
CN115645535A (zh) | 2023-01-31 |
EP3593817A1 (en) | 2020-01-15 |
EP3593817A4 (en) | 2021-04-07 |
JP2023017050A (ja) | 2023-02-02 |
CN110392579B (zh) | 2022-11-08 |
KR20190126365A (ko) | 2019-11-11 |
CN115645536A (zh) | 2023-01-31 |
CN115645535B (zh) | 2024-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7236753B2 (ja) | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 | |
RU2414904C2 (ru) | ЗАЩИТНОЕ СРЕДСТВО ДЛЯ НЕЙРОНА СЕТЧАТКИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО КОМПОНЕНТА ПРОИЗВОДНОЕ ПРОСТАГЛАНДИНА F2α | |
US20210283108A1 (en) | Method for treating neurodegenerative diseases | |
RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
JP5605659B2 (ja) | 細胞保護剤 | |
US20230321023A1 (en) | Application of regulation of eye sclera lipid metabolism to inhibit myopia | |
AU2013274582A1 (en) | Therapeutic formulation and methods of treatment | |
Kim et al. | Intraocular infestation with Thelazia callipaeda | |
KR102045044B1 (ko) | 지페노사이드 화합물을 포함하는 망막 질환 예방 또는 치료용 조성물 | |
JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および/または近視進行抑制剤 | |
WO2022123836A1 (ja) | 小児の近視進行抑制用点眼剤及び小児の近視進行抑制剤のスクリーニング方法 | |
Bali et al. | Latest update in glaucoma: The first approvals for Rho Kinase inhibitors | |
WO2022123837A1 (ja) | 強膜菲薄化治療用点眼剤及び強膜菲薄化治療剤のスクリーニング方法 | |
Samanta et al. | Cortical blindness and paraplegia following hypoxic ischemic encephalopathy as a complication of common krait bite. | |
US20240165087A1 (en) | Application of riluzole- and borneol-containing composition in preparation of medication for treating cerebrovascular diseases | |
WO2019093262A1 (ja) | 腸内環境制御による近視抑制 | |
Katz et al. | Spontaneously resolved posterior rosette cataract after sulcus‐fixed phakic lens implantation | |
JPWO2002051431A1 (ja) | 網膜虚血に基づく疾患の治療および/または予防剤 | |
Daily | thalmia usunllv starts out with an optic neuritis, and tl& he argues IKO\TS that the optic nerve plays an important part in tr-nnsmissir, ii. R. Grunfelrl. | |
Ketring | Treating glaucoma-not for the faint-hearted. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18764652 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019504597 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197029237 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018764652 Country of ref document: EP Effective date: 20191007 |